Validation Processes for Bioanalytical Methods

This technical report outlines the critical role of validation in bioanalytical methods, particularly focusing on ligand-based assays using Octet® BLI systems. It emphasizes the importance of thorough validation to ensure data accuracy and reliability, which are essential for informed decision-making in clinical diagnostics and drug development. The report details the validation process, starting with the determination of standard deviation to establish the Detection Limit (DL) and Quantitation Limit (QL). Key aspects such as assay range, robustness, stability, and linear response assessment are discussed, highlighting their significance in maintaining assay integrity. Furthermore, the report addresses the compliance of Octet® BLI systems with FDA regulations, including 21 CFR Part 11, which safeguards data integrity against manipulation. The FDA's recent advisory on the importance of data integrity in laboratory testing reinforces the need for stringent validation processes to mitigate risks associated with fraudulent data. Overall, the report advocates for a culture of quality in laboratory environments to uphold scientific integrity and public trust.